Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial

Philip McGuire; Philip Robson; Wieslaw Jerzy Cubala; Daniel Vasile; Paul Dugald Morrison; Rachel Barron; Adam Taylor; Stephen Wright

doi:10.1176/appi.ajp.2017.17030325

Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial

Philip McGuire, Philip Robson, Wieslaw Jerzy Cubala, Daniel Vasile, Paul Dugald Morrison, Rachel Barron, Adam Taylor, Stephen Wright

Research output: Contribution to journal › Article › peer-review

443 Citations (Scopus)

Abstract

Research in both animals and humans indicates that cannabidiol (CBD) has antipsychotic properties. The authors assessed the safety and effectiveness of CBD in patients with schizophrenia.

Original language	English
Pages (from-to)	225-231
Number of pages	7
Journal	The American Journal of Psychiatry
Volume	175
Issue number	3
Early online date	15 Dec 2017
DOIs	https://doi.org/10.1176/appi.ajp.2017.17030325
Publication status	Published - 1 Mar 2018

Keywords

Treatment
Schizophrenia
Cannabidiol
Psychosis
Clinical Tria

Access to Document

10.1176/appi.ajp.2017.17030325

Cite this

@article{a0a8584d14454ba2be198b0561339117,

title = "Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial",

abstract = "Research in both animals and humans indicates that cannabidiol (CBD) has antipsychotic properties. The authors assessed the safety and effectiveness of CBD in patients with schizophrenia.",

keywords = "Treatment, Schizophrenia, Cannabidiol, Psychosis, Clinical Tria",

author = "Philip McGuire and Philip Robson and Cubala, {Wieslaw Jerzy} and Daniel Vasile and Morrison, {Paul Dugald} and Rachel Barron and Adam Taylor and Stephen Wright",

year = "2018",

month = mar,

day = "1",

doi = "10.1176/appi.ajp.2017.17030325",

language = "English",

volume = "175",

pages = "225--231",

journal = "The American Journal of Psychiatry",

issn = "0002-953X",

publisher = "American Psychiatric Publishing Inc.",

number = "3",

}

TY - JOUR

T1 - Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia

T2 - A Multicenter Randomized Controlled Trial

AU - McGuire, Philip

AU - Robson, Philip

AU - Cubala, Wieslaw Jerzy

AU - Vasile, Daniel

AU - Morrison, Paul Dugald

AU - Barron, Rachel

AU - Taylor, Adam

AU - Wright, Stephen

PY - 2018/3/1

Y1 - 2018/3/1

N2 - Research in both animals and humans indicates that cannabidiol (CBD) has antipsychotic properties. The authors assessed the safety and effectiveness of CBD in patients with schizophrenia.

AB - Research in both animals and humans indicates that cannabidiol (CBD) has antipsychotic properties. The authors assessed the safety and effectiveness of CBD in patients with schizophrenia.

KW - Treatment

KW - Schizophrenia

KW - Cannabidiol

KW - Psychosis

KW - Clinical Tria

U2 - 10.1176/appi.ajp.2017.17030325

DO - 10.1176/appi.ajp.2017.17030325

M3 - Article

SN - 0002-953X

VL - 175

SP - 225

EP - 231

JO - The American Journal of Psychiatry

JF - The American Journal of Psychiatry

IS - 3

ER -

Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial

Abstract

Keywords

Access to Document

Fingerprint

Cite this